在食道腺癌中,DKK1及其受体:一个有前途的分子标
Markos Despotidis1, Orestis Lyros2, Tatiana S Driva3
1First Department of Surgery, National and Kapodistrian University of Athens, Laikon General Hospital, 11527 Athens, Greece.
Diagnostics (Basel, Switzerland)
|January 11, 2025
概括
Dickkopf-1 (DKK1) 可能通过新的途径驱动食道腺癌 (EAC),独立于Wnt信号. 准DKK1及其像CKAP4这样的受体可能为这种侵袭性癌症提供新的治疗策略.
科学领域:
- 胃肠病学 胃肠病学
- 在瘤学瘤学.
- 分子生物学分子生物学
背景情况:
- 食道腺癌 (EAC) 是一种具有较低生存率的侵袭性癌症.
- 迪克科夫 (DKK) 蛋白通常抑制Wnt/β-catenin信号传递,但可以通过Wnt独立的途径促进癌症.
- 迪克科夫-1 (DKK1) 和其新型受体,细胞骨相关蛋白4 (CKAP4) 途径与胃肠道癌症有关.
研究的目的:
- 审查DKK1及其受体在致癌过程中的作用,重点关注EAC.
- 要突出DKK1-CKAP4通路在EAC中的致癌功能.
- 强调对EAC的特定生物标志物和向治疗的需要.
主要方法:
- 对DKK1及其受体 (LRP5/6,Kremen1/2,CKAP4) 的文献综述,以及它们在EAC中的作用.
- 分析Wnt依赖和Wnt独立的信号通路,涉及DKK1.
- 在癌症进展中探索DKK1-CKAP4相互作用.
主要成果:
- DKK1可以通过Wnt独立的机制在EAC中充当瘤基因.
- DKK1-CKAP4路径在EAC中代表了一个新的致癌信号轴.
- 已建立的DKK1受体 (LRP5/6,Krm1/2) 和新型的CKAP4受体都参与其中.
结论:
- 在EAC的发展和进步中,DKK1及其与CKAP4的相互作用至关重要.
- DKK1-CKAP4通路为EAC提供了潜在的治疗标.
- 对DKK1介导信号的进一步研究对于开发新的EAC生物标志物和治疗方法至关重要.
相关概念视频
02:38Mitogens and the Cell Cycle
6.4K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
01:28Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
147
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
147
02:57Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
02:15M-Cdk Drives Transition Into Mitosis
5.5K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.5K
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
02:34Inhibition of Cdk Activity
4.6K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.6K